Company intelligence / Profile preview
Regerna Therapeutics
New York, New York, United Statesregernatx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Regerna Therapeutics is developing therapies based on modulating mRNA-binding proteins, particularly AUF1, to restore functional muscle in various forms of muscular atrophy. Preclinical data suggest benefits across reinnervation, vascularization, stem cell increase, and mitochondrial function. Clinical development is anticipated within two years.
- Therapeutic areas
- OtherEndocrinologyRare DiseasesNeurology
- Modalities
- mRNA-based drugsGene therapy (AAV delivery)Lipid nanoparticle delivery therapy (LNP)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.
Beyond the preview
Go deeper on Regerna Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Regerna Therapeutics.